Svar anti-CCP assay by Svar Life Science AB

Manufacturer Svar Life Science AB | Available Worldwide

In diagnosis of Rheumatoid Arthritis (RA), the measurement of anti-CCP is integral. People who test positive for Anti-CCP, are very likely to develop or have already developed RA, but not all who have RA, necessarily develop anti-CCP. Early detection of RA is crucial for reducing tissue damage.

Svar anti-CCP assay by Svar Life Science AB thumbnail

Svar anti-CCP assay

Request Pricing

Receive your quote directly from the manufacturer.

0 Scientists have reviewed this product

Write the First Review

No Reviews

Rheumatoid Arthritis (RA) a chronic condition that is estimated to affect around 0,5%. Early RA diagnosis can make a different to the amount of tissue damage, and in this, the detection of autoantibodies against citrullinated proteins/peptide (anti-CCP) has an important prognostic value for the disease.Along with other biomarkers (Rheumatoid Factors) are important in diagnosis of RA patients. Those who develop anti-CCP autoantibodies are very likely to develop RA, however, anti-CCP is not present in all RA patients.

The Svar CCP portfolio consists of enzyme-linked immunosorbent assay (ELISA) for detection and semi-quantitation of IgG antibodies to Cyclic Citrullinated Peptides (CCP).

Product list:

IMMUNOSCAN CCPlus^® [RA-96PLUS]

Product Overview